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possible scenarios. CONCLUSIONS: Conjoint analysis can be
used to assess the preferences of patients with schizophrenia,
and such preferences appear valid and relatively consistent.
Although further validation and reﬁnement is needed, our
results indicate that conjoint analysis is a feasible and beneﬁcial
method for measuring patient preferences among patients with
schizophrenia.
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OBJECTIVES: Different instruments are available to assess
health in individuals with psychotic illness. We aimed to identify
the complementary value of some different instruments to assess
health and health changes in schizophrenic patients.
METHODS: We analysed data from a naturalistic, prospective
cohort study, called COMETA, which involved 637 patients aged
18–40 years, 65.0% male, with schizophrenia (86.5%) or schizo-
phreniform disorder (13.5%), enrolled in 2006–2007 and fol-
lowed up to 52 weeks. Symptoms and functional changes were
assessed with the physicians’ rated scales Positive-And-Negative-
Syndrome-Scale (PANSS), Global-Assessment-of-Functioning
(GAF), Clinical-Global-Impression-Severity (CGI-S). The physi-
cians’ opinion was asked to assess compliance toward antipsy-
chotic treatment. Patients reported their attitude toward
treatment with the Drug-Attitude-Inventory (DAI-30). QoL was
assessed with EQ-5D and SF-36. We investigated whether rela-
tionships exist between scores obtained from the different scales.
RESULTS: At enrolment, signiﬁcant correlations were found
between PANSS, GAF, CGI-S scores (r, absolute value = 0.674–
0.766). Every QoL score signiﬁcantly correlated each other (r =
0.360–0.582). Correlations were lower between QoL and clinical
scores (0.189–0.393). Low correlations were estimated between
QoL scores and physicians’ reported compliance (r = 0.113–
0.282) or DAI-30 score (0.142–0.274). Each instrument showed
an average improvement in the patients’ condition after 52
weeks. However, scarce correlation was found between clini-
cians’ and patients’ reported changes. CONCLUSIONS: Both
clinicians’ and patients’ reported outcomes are necessary for a
complete evaluation of schizophrenic patients’ health. Further-
more, its brevity, and its immediateness of data reading and
interpretation are reasons for considering its introduction into
the physicians’ armamentarium for practice.
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OBJECTIVES: To present 2-year results on treatments prescribed
and their impact on quality of life (QoL) and clinical severity of
children with Attention Deﬁcit / Hyperactivity Disorder (ADHD).
METHODS:ADORE is a 2-year, prospective, international obser-
vational study in ADHD. Treatments were classiﬁed as pharma-
cotherapy, psychotherapy, pharmacotherapy and psychotherapy
combination, other, and none. As patients were allowed to change
treatment, different patients may be included in each group at
different endpoints. QoLwasmeasuredwith the ChildHealth and
Illness Proﬁle (CHIP-CE). Clinical ADHD outcomes were mea-
sured with ADHD-Rating scale parent version (ADHD-RS), CGI-
Severity scale, Children’s Global Assessment Scale (CGAS) and
Strengths and Difﬁculties Questionnaire (SDQ). Changes in out-
comes presented hereafter were estimated on all patients followed
2 years and having at least baseline and 24 months visits.
RESULTS: Among 255 French patients eligible for analysis, mean
age (SD) 8.8 years (2.3), 87.5%male, 137 (53.7%) were followed
over 24 months. Treatments were respectively at baseline and 2
years: pharmacotherapy 23.0% & 29.1%, combination
pharmacotherapy/psychotherapy 36.6% & 47.0%, psycho-
therapy 27.2% & 12.7%, other treatment 4.7% & 3.0% and
none 8.5% & 8.2%. Between baseline and 2 years, CHIP-CE
quality of life improved: mean change from baseline was +5.7
(12.9) for satisfaction, +8.6 (11.8) for achievement, +13.4 (13.0)
for risk avoidance, +5.2 (12.4) for resilience and +5.2 (9.6) for
comfort. Between baseline and 2 years, mean ADHD-RS change
was -18.3 (9.9) leading to a ﬁnal score of 21.4 (10.7) at 2 years.
CGAS mean change was +15.8 (15.5) leading to a ﬁnal score of
67.1 (16.2). Mean CGI-S change was -1.5 (1.4) leading to a ﬁnal
score of 3.2 (1.3). Rate of patients with 31 comorbidity decreased
from 76.5% to 54.0% and severity of comorbidities also
decreased. CONCLUSIONS: After 2 years, French patients suf-
fering from ADHD symptoms enrolled in this study beneﬁted
from improvement of QoL and clinical severity. Interpretation is
difﬁcult due to patients changing treatments over the study.
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OBJECTIVES: To explore the association between Sad Blue
Depressed Days (SBDD), health-related quality of life, and health
behaviors among women in a university community in Venezu-
ela. METHODS: A random sample of 71 women ranging in age
from 18 to 72 years was surveyed using a written questionnaire.
The questionnaire included the SBDD question from the Behav-
ioral Risk Factor Surveillance System (BRFSS) and the SF-36
Health Survey. The associations among SBDD, SF-36, demo-
graphics, and health behaviors were estimated computing
Pearson correlation coefﬁcients for continuous variables and
Kendall’s tau for categorical variables. RESULTS: The sample
had a mean age of 31.98 years (s.d.13.86). The prevalence of
alcohol consumption during the previous month was 63.4% and
for smoking it was 16.9%. About 60% of the sample reported no
exercising regularly during the previous month. Most of the
respondents reported sleeping problems. Respondents reported a
mean of 4.33 (s.d.7.89) SBDD in the previous 30 days. Young
women aged 18–24 years reported the highest number of SBDD
(7.51, s.d. 9.80), whereas older women aged 45+ reported the
lowest number (1.50, s.d. 3.86). About 80% of respondents
reported one or more SBDD including 18.3% who reported 14
or more SBDD. The SF-36 showed good internal consistency
reliability. Respondents scored higher in Physical Functioning
(91.76, s.d.10.53) and lower in Vitality (62.25, s.d. 20.07).
SBDD correlated signiﬁcantly with all SF-36 domains, except
Physical Functioning and Bodily Pain. SBDD was associated to
lack of regular exercise, sleeping problems, and poor perception
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